MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy

Last updated: November 21, 2023
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Esophageal Disorders

Treatment

MRI and CT

Ratiotherapy

Paclitaxel, platinum-based drug

Clinical Study ID

NCT02988921
16-161/1240
  • Ages > 18
  • All Genders

Study Summary

Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of conventional staging methods, radiation treatment planning and the assessment of tumor response in esophageal or esophagogastric cancer. This study aimed to explore the value of MRI for the prediction of tumor response to chemoradiotherapy and accurate target volume delineation as compared to CT simulation for patients with unresectable or potentially resectable esophageal or esophagogastric cancer undergoing chemoradiotherapy. The average CT texture features are also extracted before and during treatment to establish a model to predict the prognosis or side effects (e.g. radiation pneumonitis or esophagitis) of patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically confirmed squamous cell carcinoma, adenocarcinoma of the esophageal oresophagogastric junction
  • Unresectable or potentially resectable tumor (cT3-4N0-1M0-M1a, according to AJCC 6th)based on standard primary staging by EUS and CT
  • Age>18 years
  • No distant metastasis other than supraclavicular lymph nodes
  • No prior history of thoracic radiation or chemotherapy
  • Patients must have normal organ and marrow function as defined below: Leukocytes:greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normalinstitutional limits; AST/ALT: less than or equal to 1.5 times the upper limit;Creatinine within normal upper limits
  • Informed consent

Exclusion

Exclusion Criteria:

  • Contraindication for MRI scanning
  • Patients with other cancer history except cervical carcinoma in situ and non-malignantmelanoma skin cancer
  • Pregnant or lactating females
  • Contraindication for radiotherapy or chemotherapy

Study Design

Total Participants: 300
Treatment Group(s): 3
Primary Treatment: MRI and CT
Phase:
Study Start date:
October 01, 2016
Estimated Completion Date:
December 31, 2026

Study Description

  1. Both DW-MRI and CT simulation will be performed before chemoradiotherapy and after 18-22 fractions. Also MRI will be performed after treatment. The investigators will contour based on the MRI image and compare this with the standard CT plan before and during treatment.

  2. The predictive potential of initial tumor ADC, and change in ADC during and after treatment for tumor response will be assessed.

  3. The average CT texture features not only in the present study but also of those who treated previously in our department (since 2014) will be extracted before and during chemoradiotherapy to establish a model to predict the prognosis of patients.

Connect with a study center

  • Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)

    Beijing, 100021
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.